HTX 001
Alternative Names: HTX-001Latest Information Update: 28 Jun 2023
At a glance
- Originator Centre Hospitalier Universitaire Vaudois
- Developer Centre Hospitalier Universitaire Vaudois; HAYA Therapeutics
- Class Antifibrotics; Antisense oligonucleotides; Cardiovascular therapies
- Mechanism of Action Long noncoding RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Hypertrophic cardiomyopathy; Unspecified